1Beljaars L,Molema G,Weert B,et al.Albumin modified with mannose 6-phosphate:A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells[J].Hepatology.1999,29:1486-1493.
2Greupink R,Bakker HI,Bouma W,et al.The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo[J].J Pharmacol Exp Ther.2006,317:514-521.
3Gonzalo T,Beljaars L,van de Bovenkamp M,et al.Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells[J].J Pharmacol Exp Ther.2007,321:856-865.
4Sato Y,Murase K,Kato J,et al.Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone[J].Nat Biotechnol.2008,26:431-442.
5Elrick LJ,Leel V,Blaylock MG,et al.Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells–a potential mechanism for targeting liver anti-fibrotic therapeutics[J].J Hepatol.2005,42:888-896.
6Kim SI,Shin D,Choi TH,et al.Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I[J].Mol Ther.2007,15:1145-1152.
7Herrmann J,Arias M,Van De Leur E,et al.CSRP2,TIMP-1,and SM22α promoter fragments direct hepatic stellate cell-specific transgene expression in vitro,but not in vivo[J].Liver Int 2004,24:69-79.
8Inagaki Y,Kushida M,Higashi K,et al.Cell type-specific intervention of transforming growth factor β/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice[J].Gastroenterology.2005,129:259-268.
9Kinoshita K,Iimuro Y,Fujimoto J,et al.Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis[J].Gut.2007,56:396-404.
10Cassiman D,Libbrecht L,Desmet V,et al.Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers[J].J Hepatol.2002,36:200-209.
二级参考文献17
1Okazaki I, Watanabe T, Hozawa S, et al. Molecular mechanism of the reversibility of hepatic fibrosis: with special reference to the role of matrix metalloproteinases[J]. J Gastroenterol Hepatol, 2000, 15 Suppl: D26-32.
2Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions [J]. Eur J Cell Biol, 1997, 74(2) :111-122.
3Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis [ J ]. Am J Physiol Gastrointest Liver Physiol, 2000, 279 (2) : G245 -G249.
4Sakaida I, Hironaka K, Kimura T, et al. Herbal medicine Sho-saiko-to (T J-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases ( TIMPs ) in rat stellate cell [J]. Life Sci, 2004, 74(18):2251-2263.
5Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo [ J ]. J Biol Chem, 2000, 275 (34):26411- 26415.
6Jo Y, Yeon J, Kim HJ, et al. Analysis of tissue inhibitor of metalloprotein- ases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baeulovirus/insect-cell expression system [J], Biochem J, 2000, 345 Pt 3:511-519.
7Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study[J]. J Biol Chem, 1998, 273 (2) :871-880.
8Hu YB, Li DG, Lu HM. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatie fibrogenesis in rats [ J ]. J Gene Med, 2007, 9(3): 217-229.
9Karande P, Jain A, Mitragotri S. Discovery of transderrnal penetration enhancers by high-throughput screening[ J ]. Nat Biotechnol, 2004, 22 (2) : 192-197.
10Gautam A, Densmore CL, Xu B, et al. Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery[J]. Mol Ther, 2000, 2( 1 ) : 63 -70.
